Advertisement
BBIO vs KURA
Which Stock Would AI Choose? BridgeBio Pharma (BBIO) vs. Kura Oncology (KURA) Stock Comparison
Key Takeaways
- BridgeBio Pharma (BBIO) has delivered over 105% one-year returns, significantly outperforming Kura Oncology (KURA)'s 41% gain, driven by phase 3 trial successes.
- BBIO commands a market cap of $14.4 billion, dwarfing KURA's $805 million, reflecting greater scale in the biotech sector.
- Recent clinical data has fueled momentum for both, with KURA rallying 8% on renal cell carcinoma study results and BBIO benefiting from rare disease advancements.
- Analyst price targets indicate substantial upside: $100+ average for BBIO and $31 for KURA, signaling positive market positioning.
- Both stocks exhibit biotech volatility, but BBIO's diversified pipeline offers relative stability compared to KURA's oncology focus.
Introduction
BridgeBio Pharma (BBIO) and Kura Oncology (KURA) represent compelling opportunities in the biotech sector, where clinical milestones often drive sharp price movements. Both companies focus on precision therapies—BBIO targeting genetic diseases and KURA oncology indications—making them relevant for traders eyeing momentum plays and investors seeking exposure to innovative pipelines. This stock comparison analyzes their recent performance, catalysts, and relative strengths amid evolving market sentiment, aiding decisions in a high-volatility environment dominated by trial data and analyst views.
BBIO Overview and Recent Performance
BridgeBio Pharma (BBIO) develops therapies for genetic diseases and cancers, with a portfolio spanning rare conditions like transthyretin amyloidosis (ATTR) and achondroplasia. In recent market activity, BBIO shares have trended upward, supported by multiple phase 3 trial successes that reinforce its growth trajectory. The stock has achieved over 100% gains in the past year, trading near $74 with a 52-week range of $31.77 to $84.94. Sentiment has shifted positively due to analyst upgrades, including Mizuho raising its price target to $106, and strategic appointments like a new CEO at its oncology unit. These developments have enhanced investor confidence amid broader biotech M&A interest.
KURA Overview and Recent Performance
Kura Oncology (KURA) specializes in precision medicines for cancer, highlighted by ziftomenib for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML, a blood cancer) and darifarnib combinations. Recent weeks have seen KURA shares rally, including an 8% surge on preliminary data showing robust activity in clear cell renal cell carcinoma (a kidney cancer) patients pretreated with cabozantinib. Trading around $9, the stock reflects 41% one-year appreciation and YTD gains of about 13%, with a 52-week range of $5.45 to $12.49. Key influences include the Komzifti (ziftomenib) launch generating initial revenue and a Japanese phase 2 trial initiation, bolstering oncology-focused sentiment despite clinical risks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform’s top-performing AI trading bots, drawn from hundreds available that trade thousands of tickers across diverse strategies. Out of over 350 bots, approximately 25 trending ones are highlighted as most suitable for current market conditions, spanning AI Trading Signal Agents, Virtual Agents, and Brokerage Agents. These bots vary in timeframes (from 5-minute to longer horizons), trading styles (technical or fundamental analysis), risk levels (low to high volatility), and asset classes, enabling users to copy proven patterns like swing trades or scalping. This dynamic leaderboard helps traders identify bots aligned with biotech momentum or sector rotations, offering a data-driven edge. Explore the Trending AI Robots to evaluate options for your portfolio.
Head-to-Head Comparison
BridgeBio Pharma (BBIO) and Kura Oncology (KURA) both operate in biotech but diverge in focus: BBIO’s diversified model across genetic disorders provides multiple growth drivers, while KURA concentrates on oncology precision therapies like menin inhibitors. Recent momentum favors BBIO with superior returns and scale, versus KURA’s event-driven spikes. Risk factors are comparable—clinical trial outcomes and cash burn—but BBIO’s larger revenue ($502M ttm vs. $67M) and market cap offer stability. Sector exposure ties both to healthcare volatility, yet BBIO benefits from rare disease tailwinds and KURA from cancer trial catalysts, presenting trade-offs in relative performance and sentiment.
Tickeron AI Verdict
Tickeron’s AI currently favors BridgeBio Pharma (BBIO) over Kura Oncology (KURA), based on stronger trend consistency, larger scale, and multiple recent catalysts like phase 3 wins. While KURA shows promise in oncology data, BBIO’s superior relative positioning and analyst support suggest higher probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a Buy and KURA is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBIO’s FA Score shows that 1 FA rating(s) are green whileKURA’s FA Score has 0 green FA rating(s).
- BBIO’s FA Score: 1 green, 4 red.
- KURA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBIO’s TA Score shows that 3 TA indicator(s) are bullish while KURA’s TA Score has 6 bullish TA indicator(s).
- BBIO’s TA Score: 3 bullish, 3 bearish.
- KURA’s TA Score: 6 bullish, 5 bearish.
Price Growth
BBIO (@Biotechnology) experienced а +1.32% price change this week, while KURA (@Biotechnology) price change was +8.60% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.
Reported Earning Dates
BBIO is expected to report earnings on Jul 30, 2026.
KURA is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+7.11% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BBIO | KURA | BBIO / KURA | |
| Capitalization | 13.5B | 920M | 1,467% |
| EBITDA | -535.2M | -291.88M | 183% |
| Gain YTD | -9.923 | -0.289 | 3,437% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 580M | 71.6M | 810% |
| Total Cash | 940M | 581M | 162% |
| Total Debt | 2.49B | 24.3M | 10,255% |
BBIO | KURA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 85 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 51 | 43 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 12 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BBIO's Valuation (3) in the null industry is somewhat better than the same rating for KURA (51) in the Biotechnology industry. This means that BBIO’s stock grew somewhat faster than KURA’s over the last 12 months.
BBIO's Profit vs Risk Rating (85) in the null industry is in the same range as KURA (100) in the Biotechnology industry. This means that BBIO’s stock grew similarly to KURA’s over the last 12 months.
KURA's SMR Rating (99) in the Biotechnology industry is in the same range as BBIO (100) in the null industry. This means that KURA’s stock grew similarly to BBIO’s over the last 12 months.
KURA's Price Growth Rating (43) in the Biotechnology industry is in the same range as BBIO (51) in the null industry. This means that KURA’s stock grew similarly to BBIO’s over the last 12 months.
KURA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BBIO (100) in the null industry. This means that KURA’s stock grew similarly to BBIO’s over the last 12 months.
| BBIO | KURA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 76% |
| Advances ODDS (%) | 19 days ago 80% | 2 days ago 79% |
| Declines ODDS (%) | 22 days ago 80% | 16 days ago 82% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 88% |
Advertisement
BBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | +3.97% | ||
| AXON - BBIO | 44% Loosely correlated | -3.16% | ||
| ARRY - BBIO | 43% Loosely correlated | +6.75% | ||
| PMN - BBIO | 43% Loosely correlated | +1.28% | ||
| KURA - BBIO | 41% Loosely correlated | +4.33% | ||
| DYN - BBIO | 39% Loosely correlated | +5.51% | ||
More | ||||
KURA and
Correlation & Price change
A.I.dvisor indicates that over the last year, KURA has been loosely correlated with IMVT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To KURA | 1D Price Change % | ||
|---|---|---|---|---|
| KURA | 100% | +4.33% | ||
| IMVT - KURA | 52% Loosely correlated | +7.81% | ||
| VYGR - KURA | 51% Loosely correlated | N/A | ||
| XNCR - KURA | 51% Loosely correlated | +10.84% | ||
| IMNM - KURA | 50% Loosely correlated | +2.35% | ||
| NRIX - KURA | 50% Loosely correlated | +6.27% | ||
More | ||||